Pharma CEO Guide to Medical Affairs Operations
The pharma CEO guide to medical affairs operations begins with a positioning clarification that matters enormously for how you build and govern this function. Medical affairs is not a support function for commercial. It is a scientific leadership function that generates evidence, builds medical credibility, shapes clinical practice, and creates the trust infrastructure that a pharma company’s commercial and regulatory operations ultimately depend on.
CEOs who build medical affairs as a commercial enabler rather than as an independent scientific function consistently underperform on the dimensions that matter most: KOL credibility, payer scientific engagement, regulatory relationship quality, and long-term pipeline positioning. This guide is for pharma CEOs who want to build medical affairs operations that are genuinely excellent, not simply compliant.
The Medical Affairs Strategic Mandate
Medical affairs has evolved significantly over the past decade. What was once primarily a field-based function responsible for responding to unsolicited medical information requests and coordinating advisory boards has become a strategic function that drives evidence generation strategy, leads health economic and outcomes research, shapes clinical guidelines, and serves as the primary scientific interface with payers, healthcare systems, and regulatory bodies.
According to McKinsey analysis of pharmaceutical value creation, companies that invest in building differentiated medical affairs capabilities generate significantly higher commercial returns on their pipeline assets, particularly in complex therapeutic categories where clinical decision-making is nuanced and payer scrutiny is intense. The mechanism is straightforward: strong medical affairs operations generate the evidence that makes reimbursement decisions favorable, creates the clinical credibility that makes KOL advocacy authentic, and builds the scientific relationships that support regulatory flexibility.
The CEO’s role is to set the strategic positioning of medical affairs, ensure adequate resourcing relative to pipeline ambition, establish the governance that protects medical affairs independence while enabling commercial alignment, and build the medical leadership team that can execute across all these dimensions.
Building KOL Engagement Programs
Key opinion leader (KOL) engagement is the most visible component of medical affairs operations and also one of the most complex to execute well. KOL relationships are built on scientific credibility and mutual respect, not on financial transactions. Companies that treat KOL engagement primarily as a promotional tactic undermine the very credibility they are trying to leverage.
Build a KOL engagement strategy that starts with segmentation: not all KOLs are equally important for all purposes. National thought leaders who influence clinical guidelines and regulatory discussions require a different engagement approach than regional academic leaders who influence local practice, which differs again from community practice leaders who have high prescribing influence but limited research engagement.
For each tier of KOL engagement, define the purpose of the relationship: clinical research collaboration, advisory board participation, scientific education, data dissemination, or some combination. The purpose shapes the nature of interactions, the fair market value compensation rates, and the compliance requirements governing documentation. Build a KOL engagement plan for each major therapeutic area or product that maps the KOL landscape, identifies engagement priorities, and tracks relationship development against milestones.
Medical science liaisons (MSLs) are the primary relationship-builders in KOL engagement. MSL effectiveness depends on scientific credibility, relationship skills, and operational discipline. Build MSL performance metrics that balance scientific engagement depth with coverage breadth, and that reward relationship quality over activity volume. MSLs who generate a high volume of low-quality interactions are less valuable than MSLs who cultivate deep scientific partnerships with a smaller number of strategically critical thought leaders.
MSL territory alignment should be driven by KOL concentration and clinical practice patterns, not simply by geography. Academic medical centers with high concentrations of research-active KOLs may require dedicated MSL coverage even if their geographic footprint is small. Build a territory design methodology for MSLs that is distinct from sales force territory design and is calibrated to scientific engagement objectives rather than prescribing volume.
Track KOL engagement through a purpose-built CRM or a dedicated module within the broader CRM system. Each KOL record should capture relationship history, publications, clinical trial participation, advisory board involvement, grant history, and relevant compliance documentation. This record should be accessible to MSLs, medical directors, and market access teams to enable coordinated scientific engagement.
Managing Medical Information Request Workflows
Medical information (MI) operations are among the most regulated and most operationally demanding functions in medical affairs. The MI function receives and responds to unsolicited requests for scientific information from healthcare providers, patients, payers, and other stakeholders. Every response must be accurate, balanced, referenced to published literature, and consistent with applicable regulatory requirements.
Build a medical information infrastructure that includes a documented intake process, a response library of standard response documents (SRDs) for frequently asked questions, a quality assurance review process for custom responses, and a tracking system that captures inquiry volume, topics, and turnaround times.
The SRD library is the operational core of MI efficiency. Well-maintained SRDs allow MI specialists to respond to the majority of inquiries quickly and consistently, reserving custom research and response development for truly novel questions. Build a process for SRD development, review, and maintenance that ensures every SRD is scientifically current, approved by medical leadership, and updated within thirty days of any relevant new data publication.
Turnaround time standards should be defined by inquiry type and urgency. Urgent safety-related inquiries should receive same-day responses. Standard scientific inquiries should be addressed within three to five business days for SRD-available questions and within ten business days for custom responses. Track performance against these standards monthly and review trends in inquiry volume and topic distribution to identify emerging clinical questions that may warrant proactive scientific communications.
Adverse event identification is a compliance responsibility embedded in MI operations. Every member of the MI team must be trained to identify adverse event reports embedded in MI inquiries, escalate them immediately to pharmacovigilance, and document the escalation. Build a workflow that integrates MI and pharmacovigilance at the operational level, with clear escalation protocols and dual-system documentation requirements.
Coordinating Clinical Publication Planning
Publication planning is the process by which medical affairs ensures that clinical trial results and other significant data are communicated to the scientific community through peer-reviewed publications, conference presentations, and other scientific channels. Strong publication planning amplifies the scientific value of clinical investments; weak publication planning results in data that is generated but not effectively communicated.
Build a publication planning process that covers all key data assets across the product portfolio. For each major clinical trial, define the publication strategy: which data will be published, in which journals, on what timeline, with which authors. Publication planning should begin while the clinical trial is ongoing, not after results are available.
Author selection is a critical and compliance-sensitive element of publication planning. Authors must meet ICMJE authorship criteria, which require meaningful intellectual contribution to the work. Company employees can be listed as authors when they meet these criteria and are identified as company employees. External academic authors who serve as lead or corresponding authors must have had genuine involvement in study design, data analysis, or interpretation. Ghost authorship, the practice of listing academic authors who did not meaningfully contribute, is a serious compliance and integrity violation that must be actively prevented through policy and training.
Medical writing operations require dedicated resources and strong project management. Build a publication tracker that documents each planned publication with target journal, planned submission date, current status, and assigned medical writer. Review the publication tracker monthly in the medical affairs leadership team meeting and quarterly with commercial leadership to ensure publication timing is aligned with lifecycle management priorities and launch timing.
Congress presentation planning is a parallel operational workload that requires coordination between medical affairs, commercial, and corporate communications. Major scientific conferences such as ASCO, ASH, ADA, ACC, and ESC are both scientific events and commercial moments. Build a congress planning process that coordinates abstract submission, satellite symposia programming, advisory board meetings, press strategy, and field communications around key data presentations.
Building Health Economic Evidence Generation Programs
Health economic and outcomes research (HEOR) has become a central component of medical affairs operations as payer decision-making has become increasingly sophisticated and evidence-dependent. HEOR generates the value evidence that supports formulary placement, prior authorization criteria design, step therapy policy, and outcomes-based contracting.
Build a HEOR strategy that is anchored to the payer value story for each product and that identifies the specific evidence gaps that payers are using to justify restrictive coverage policies. The HEOR strategic plan should define: which evidence types are highest priority (cost-effectiveness models, budget impact models, real-world comparative effectiveness, patient-reported outcomes), which data sources are available or accessible, what the development timeline is, and how evidence will be disseminated to payer audiences.
Real-world evidence (RWE) generation is now a core HEOR capability. Build or access relationships with health system data partners, claims data vendors, and patient registry networks that can provide the real-world patient population data needed for RWE studies. Develop an RWE governance process that includes protocol review, IRB oversight where required, data use agreement management, and publication planning.
HEOR dissemination is as important as HEOR generation. Building rigorous health economic models that sit in databases without reaching payer decision-makers generates zero value. Build a HEOR dissemination plan that identifies the payer audience for each evidence asset, defines the channel (peer-reviewed publication, conference presentation, payer value dossier, direct payer presentation), and assigns accountability for dissemination execution.
Managing Advisory Board Operations
Advisory boards are among the most valuable and most compliance-intensive activities in medical affairs. A well-run advisory board generates genuine scientific insights from leading clinicians, builds deep relationships with key opinion leaders, and provides strategic guidance on evidence generation, medical education, and clinical positioning. A poorly run advisory board generates compliance risk, erodes KOL credibility, and produces outputs that no one uses.
Build an advisory board operations framework that covers the full lifecycle: strategic purpose definition, participant identification and selection, agenda design, facilitation planning, documentation, output utilization, and compensation and compliance management.
Strategic purpose is the most important element. Every advisory board should have a clear, specific question it is intended to answer or a genuine strategic decision it is intended to inform. “Hearing from key opinion leaders” is not a strategic purpose. “Getting expert input on the clinical study design for our Phase 3 extension study” or “Understanding prescribing barriers in patients who have failed prior therapy” is a strategic purpose.
Participant selection should be based on scientific expertise and clinical perspective relevant to the advisory board purpose. Fair market value compensation must be established for each participant type and documented through a compliant process. Use a third-party fair market value assessment to set compensation ranges and review rates annually.
Agenda design should be driven by the questions the company genuinely needs answered, not by what the company wants to present to KOLs. Advisory boards that are primarily presentations by company staff with minimal substantive expert discussion are compliance risks and waste KOL time. Build agendas that are discussion-heavy, where expert input is genuinely sought and recorded.
Document advisory board outputs rigorously: key insights, recommendations, and their connection to the strategic purpose. Distribute a summary of outputs to participants and to internal stakeholders. Build a tracking system that follows up on advisory board recommendations and documents how they were incorporated into strategy or why they were not adopted.
The connection between medical affairs advisory operations and commercial strategy is a key alignment point, as described in our pharma commercial ops framework.
Aligning Medical Affairs with Commercial and R&D Strategy
Medical affairs sits at the intersection of commercial and R&D, and building effective alignment across these three functions is one of the CEO’s most important governance responsibilities.
At the commercial interface, medical affairs provides the scientific credibility that makes commercial operations trusted: medical education programs that reflect genuine clinical science, MSL scientific exchange that does not cross into promotion, and payer evidence that supports market access without overstating commercial claims. Build formal alignment mechanisms between medical affairs and commercial that include joint planning processes, shared data dashboards, and regular leadership dialogue, while maintaining the structural independence of medical affairs from commercial reporting lines.
At the R&D interface, medical affairs provides the external scientific intelligence that informs pipeline decisions: KOL insights on unmet medical needs, real-world evidence on current treatment patterns and outcomes gaps, and payer evidence perspectives that should inform trial design. Build a structured process for medical affairs to contribute scientific intelligence to pipeline portfolio reviews and clinical development planning discussions.
Medical affairs leadership should participate in the annual commercial planning process and the R&D portfolio review. These are not courtesy seats. Medical affairs leadership should bring substantive scientific intelligence to both conversations and should have defined decision rights in the areas where medical affairs expertise is essential: evidence generation priorities, scientific communications strategy, and KOL engagement planning.
For the clinical development side of this alignment, see how clinical and medical affairs work together in the pharma clinical ops framework.
Measuring Medical Affairs Effectiveness
Medical affairs effectiveness measurement is an evolving discipline. The challenge is that many of the most important medical affairs outcomes, such as KOL advocacy, clinical guideline influence, and payer scientific credibility, are difficult to measure directly. Building a measurement framework that captures both quantitative outputs and qualitative outcomes is essential for demonstrating medical affairs value and for managing the function effectively.
Build a medical affairs scorecard that includes: MSL engagement metrics (number of scientific interactions, reach across KOL tiers, engagement quality ratings), MI operations metrics (inquiry volume, turnaround time, SRD utilization), publication metrics (planned versus actual publication delivery, journal impact factor targets), HEOR metrics (evidence generation against plan, payer dossier submissions), and advisory board metrics (advisory board volume, output utilization rate).
Supplement quantitative metrics with qualitative assessments: KOL perception surveys, payer scientific engagement feedback, and cross-functional assessments from commercial and R&D partners. These qualitative data points are often more informative than output metrics for understanding whether medical affairs is generating genuine scientific value or merely completing activities.
Review the medical affairs scorecard monthly at the medical affairs leadership level and quarterly at the CEO and executive committee level. Use scorecard data to make resource allocation decisions, identify capability gaps, and demonstrate medical affairs ROI in budget planning cycles.
Conclusion
Related Reading
For further context, explore Pharma CEO Guide to Business Development Operations and Pharma CEO Guide to Business Operations Management.